PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-5.66%
Negative revenue growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-4.38%
Negative gross profit growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would suspect poor product pricing or inefficient production.
-15.27%
Negative EBIT growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-23.77%
Negative operating income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-15.66%
Negative net income growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-15.66%
Negative EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-15.66%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
74.19%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 0.97%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
66.93%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 16.84%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
36.33%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 5.61%. Joel Greenblatt might see a short-term competitive advantage at play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
197.70%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 31.50% over a decade. Joel Greenblatt might see a standout compounder of earnings.
61.57%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 31.50%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
48.90%
3Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 7.82%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
222.31%
Equity/share CAGR of 222.31% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
133.90%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 41.13%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
65.83%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 9.75%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
-10.00%
Dividend cuts or stagnation while Medical - Pharmaceuticals median is 0.00%. Seth Klarman sees a disadvantage in shareholder returns vs. peers.
50.00%
3Y dividend/share CAGR of 50.00% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
147.76%
AR growth of 147.76% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
8.38%
Inventory growth of 8.38% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
1.02%
Asset growth of 1.02% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
3.65%
BV/share growth of 3.65% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-7.61%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
1.36%
SG&A dropping significantly vs. Medical - Pharmaceuticals median. Joel Greenblatt sees near-term margin upside but checks for underinvestment risk.